Authors: A Martin Lerner, Safedin Beqaj:
Valacyclovir and valganciclovir inhibit viral EBV, HCMV, or HHV6 replication by inhibiting the core proteins, DNA polymerase, and thymidine kinase, which occupy
approximately the 50th gene of the early, middle, and late sequential cascade of the several hundred herpesvirus genes in each of the three genomes.
The murine retrovirus XMRV may compromise immune function in ME/CFS patients, facilitating nonpermissive herpesvirus replication.16,17
We suggest that in ME/CFS patients, valacyclovir and valganciclovir inhibit the herpesvirus lytic replication cycle and thus prevent “recruitment of new host cells to ME/CFS patients” and indirectly inhibit nonpermissive virus replication, thereby facilitating recovery from ME/CFS illness18
Surprisingly, after beginning valacyclovir/valganciclovir, the earliest time at which clinical improvement began was 6 months, which is far beyond what might customarily be expected.
See also: If you take longterm Valtrex - READ THIS! or See also: Herpesvirus antiviral treatment reversed CFS illness in 79 of 106 Group A CFS patients